XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet Oncology
(Thomson Reuters ONE) -
Report Highlights Efficacy of New Antibody Therapy in Advanced Colorectal Cancer
AUSTIN, Texas, Jan. 17, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT)
today announced the publication of results from its pivotal phase 3 trial of the
Company's lead monoclonal antibody therapy. The results were published in The
Lancet Oncology in an article titled, "MABp1 as a Novel Antibody Treatment for
Advanced Colorectal Cancer: A Randomised, Double-Blind, Placebo-Controlled,
Phase 3 Study." The article is now available online.
"The findings indicate what we believe to be the first evidence that antibodies
produced as a result of a natural human immune response can play a role in
regulating disease progression in cancer," said Prof. Tamas Hickish, lead author
and Chair of the European Phase 3 Study. He stated, "The antibody was evaluated
on the basis of how it improves health status as it antagonizes the disease."
And further, "Its risk benefit profile represents a new standard of care."
Jolanta Gore-Booth, CEO of Europacolon, Europe's leading colorectal cancer
patient organization, said, "As a natural human antibody, we are delighted that
patients who are already compromised from previous treatments are not subjected
to the further effects of toxic drugs. A treatment for advanced cancer that
helps improve patient health, or should we say wellbeing, has been long
awaited!"
About Colorectal Cancer
Colorectal cancer is the second leading cause of malignancy in the
industrialized world1. Because the incidence of colorectal cancer increases
with economic development and aging, incidence is rising worldwide2. In Europe,
approximately 470,000 patients will be diagnosed with colorectal cancer this
year, and half will progress and ultimately succumb to the disease3. Disease
progression is associated with significant morbidity, functional impairment and
failure of multiple therapies, often with substantial toxicities. People with
advanced disease are thus symptomatic and often unable to tolerate further
treatment-related side effects, leaving an urgent need for more effective, less
toxic therapies for these patients.
About True Human(TM) Therapeutic Antibodies
Unlike previous generations of antibody therapies, XBiotech's True Human(TM)
antibodies are derived without modification from individuals who possess natural
immunity to certain diseases. With discovery and clinical programs across
multiple disease areas, XBiotech's True Human antibodies have the potential to
harness the body's natural immunity to fight disease with increased safety,
efficacy and tolerability.
About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of therapeutic
antibodies based on its True Human(TM) proprietary technology. XBiotech
currently is advancing a robust pipeline of antibody therapies to redefine the
standards of care in oncology, inflammatory conditions and infectious diseases.
Headquartered in Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more rapidly, cost-
effectively and flexibly produce new therapies urgently needed by patients
worldwide. For more information, visit www.xbiotech.com.
About The Lancet Oncology
The Lancet Oncology is considered the leading publication worldwide for
clinical oncology research4. The Lancet Oncology is ranked among the top three
of the world's leading oncology Journals and is in the top 0.5% of all
scientific journals, of any discipline.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations
regarding management's beliefs and expectations that involve substantial risks
and uncertainties. In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "would," "could," "expects,"
"plans," "contemplate," "anticipates," "believes," "estimates," "predicts,"
"projects," "intend" or "continue" or the negative of such terms or other
comparable terminology, although not all forward-looking statements contain
these identifying words. Forward-looking statements are subject to inherent
risks and uncertainties in predicting future results and conditions that could
cause the actual results to differ materially from those projected in these
forward-looking statements. These risks and uncertainties are subject to the
disclosures set forth in the "Risk Factors" section of certain of our SEC
filings. Forward-looking statements are not guarantees of future performance,
and our actual results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ materially from the
forward-looking statements contained in this press release. Any forward-looking
statements that we make in this press release speak only as of the date of this
press release. We assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise, after the
date of this press release.
1 Lozano R, et al. Global and regional mortality from 235 causes of death for
20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of
Disease Study 2010. Lancet 2012;380: 2095e128.
2 United European Gastroenterology (UEG). https://www.ueg.eu/press/releases/ueg-
press-release/article/europe-is-falling-behind-america-in-the-fight-against-
colorectal-cancer-due-to-low-screening-uptake/. Accessed April, 2016.
3 EuropaColon. http://www.europacolon.com/crcstatistics.php?
Action=Crcstatistics. Accessed April, 2016.
4 2013 Journal Citation Reports®, Thomson Reuters 2014.
Contact
Ashley Otero
aotero(at)xbiotech.com
512-386-2930
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 17.01.2017 - 14:00 Uhr
Sprache: Deutsch
News-ID 518091
Anzahl Zeichen: 6833
contact information:
Town:
Austin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 157 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet Oncology"
steht unter der journalistisch-redaktionellen Verantwortung von
XBiotech, Inc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
